Tech Company Financing Transactions

Jnana Therapeutics Funding Round

Jnana Therapeutics, operating out of Boston, secured $107 million from Bain Capital Life Sciences, Avalon Ventures and Pfizer Venture Investments.

Transaction Overview

Company Name
Jnana Therapeutics
Announced On
11/15/2022
Transaction Type
Venture Equity
Amount
$107,000,000
Round
Series C
Investors

Bain Capital Life Sciences (Lead Investor)

Avalon Ventures (Kevin Kinsella)

Pfizer Venture Investments

Polaris Partners (Amir Nashat)

RA Capital (Matthew Hammond)

Versant Ventures (Carlo Rizzuto)

Proceeds Purpose
The company intends to use the funds to progress its lead program in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and to advance additional wholly owned, potential first-in-class medicines in immune-mediated diseases and cancer.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6 Tide St.
Boston, MA 02210
USA
Phone
Undisclosed
Website
www.jnanatx.com
Email Address
[email protected]
Overview
Jnana is building the first drug discovery platform dedicated to SLC transporters.
Profile
Jnana Therapeutics LinkedIn Company Profile
Social Media
Jnana Therapeutics Company Twitter Account
Company News
Jnana Therapeutics News
Facebook
Jnana Therapeutics on Facebook
YouTube
Jnana Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Joanne Kotz
  Joanne Kotz LinkedIn Profile  Joanne Kotz Twitter Account  Joanne Kotz News  Joanne Kotz on Facebook
Chief Scientific Officer
Joel Barrish
  Joel Barrish LinkedIn Profile  Joel Barrish Twitter Account  Joel Barrish News  Joel Barrish on Facebook
Vice President
Heather Blanchette
  Heather Blanchette LinkedIn Profile  Heather Blanchette Twitter Account  Heather Blanchette News  Heather Blanchette on Facebook
Vice President
Dean Brown
  Dean Brown LinkedIn Profile  Dean Brown Twitter Account  Dean Brown News  Dean Brown on Facebook
Vice President
Nick Pullen
  Nick Pullen LinkedIn Profile  Nick Pullen Twitter Account  Nick Pullen News  Nick Pullen on Facebook
VP - Bus. Development
Caroline Beer
  Caroline Beer LinkedIn Profile  Caroline Beer Twitter Account  Caroline Beer News  Caroline Beer on Facebook
VP - Finance
Brian Danieli
  Brian Danieli LinkedIn Profile  Brian Danieli Twitter Account  Brian Danieli News  Brian Danieli on Facebook
VP - Human Resources
Danielle Abdelahad
  Danielle Abdelahad LinkedIn Profile  Danielle Abdelahad Twitter Account  Danielle Abdelahad News  Danielle Abdelahad on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/15/2022: IntelliProve venture capital transaction
Next: 11/15/2022: Primer Labs venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.